Dose-dependent retrograde facilitation of verbal memory in healthy elderly after acute oral lorazepam administration

Psychopharmacology
Nunzio PomaraJohn J Sidtis

Abstract

Retrograde facilitation (RF) refers to a paradoxical phenomenon in which recall of information presented before acute administration of agents generally associated with anterograde amnestic and sedative effects, such as benzodiazepines, is enhanced relative to a placebo condition. However, it is unclear whether this effect occurs in elderly individuals and if it is influenced by plasma drug levels, baseline cognitive function, or genetic factors such as the APOE e-4 allele, that may modulate drug-induced cognitive toxicity. To determine if acute oral doses of lorazepam (0.5 mg, 1 mg) produced RF in elderly individuals exposed to interference tasks, and the variables associated with RF. Sixty-four cognitively intact and highly educated (>12 years) older adults (mean age, 66.09 years) participated in a placebo-controlled double-blind crossover study. The Buschke Selective Reminding Test was used to assess RF and amnestic effects for verbal memory. Self-ratings of mood states were also obtained. Lorazepam administration resulted in significant dose-dependent RF, i.e., better recall of pre-drug word lists compared to placebo [F(1,63)= 15.358; p<0.001 and F(1,63)= 46.163; p<0.001 for 0.5 and 1 mg lorazepam, respectively]. Also, more...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jan 1, 1987·Acta Neuropathologica·R J Seitz, W Wechsler
Nov 1, 1987·Urology·M S KaplanM C Benson
Jan 1, 1984·Psychopharmacology·J V HinrichsS P Mewaldt
Dec 1, 1983·Perceptual and Motor Skills·R Berchou, R I Block
Sep 1, 1995·Nature Medicine·S SorbiL Amaducci
Mar 23, 1995·The New England Journal of Medicine·S R CummingsT M Vogt
Mar 1, 1995·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·A FoyJ Halliday
Dec 1, 1993·Scandinavian Journal of Social Medicine·O P RyynänenV Saano
Jul 1, 1996·Annals of Neurology·B T HymanR Wallace
Jul 1, 1996·Age and Ageing·C I NeutelS B Patten
Aug 10, 1999·Journal of Clinical Psychopharmacology·S E FileE M Joyce
May 17, 2000·Proceedings of the National Academy of Sciences of the United States of America·G W SmallM E Phelps
Sep 25, 2001·American Journal of Medical Genetics·J H LeeR Mayeux
Nov 20, 2001·Psychopharmacology·M T FillmoreL Hays
Jan 15, 2002·Genetic Epidemiology·Douglas C Ewbank
Apr 10, 2002·Archives of Neurology·Scott MarquisRichard Camicioli
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Jan 22, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nunzio PomaraJohn J Sidtis
Jan 28, 2004·Annual Review of Psychology·John T Wixted
Feb 9, 2005·Archives of General Psychiatry·Nunzio PomaraJohn J Sidtis
Jan 1, 1993·Journal of Psychopharmacology·H J WeingartnerR G Lister
Mar 1, 1973·Memory & Cognition·L Postman, B J Underwood

❮ Previous
Next ❯

Citations

Apr 27, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Nunzio PomaraJohn J Sidtis
Apr 26, 2013·Journal of Gerontological Nursing·Nicole J Brandt, Jessica Pythtila
May 1, 2007·Reumatología clinica·Lola Roldán-TapiaMatías Valverde
Feb 5, 2008·Critical Care Clinics·Margaret S HerridgeRamona O Hopkins

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.